|
US6908744B1
(en)
*
|
2000-03-14 |
2005-06-21 |
Regeneron Pharmaceuticals, Inc. |
Methods of stimulating cartilage formation
|
|
DK1311661T3
(da)
*
|
2000-08-14 |
2012-11-26 |
Us Gov Health & Human Serv |
Forøget homolog rekombination medieret ved lambda-rekombinationsproteiner
|
|
US20050144655A1
(en)
|
2000-10-31 |
2005-06-30 |
Economides Aris N. |
Methods of modifying eukaryotic cells
|
|
US6586251B2
(en)
*
|
2000-10-31 |
2003-07-01 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
US6596541B2
(en)
|
2000-10-31 |
2003-07-22 |
Regeneron Pharmaceuticals, Inc. |
Methods of modifying eukaryotic cells
|
|
GB0110029D0
(en)
|
2001-04-24 |
2001-06-13 |
Grosveld Frank |
Transgenic animal
|
|
EP1543110A4
(en)
|
2002-05-17 |
2006-09-06 |
Sinai School Medicine |
POPULATION OF DEFINITIVE ENDODERMIC CELLS AND MESODERMAL
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
DK2314629T4
(da)
|
2002-07-18 |
2023-02-06 |
Merus Nv |
Rekombinant produktion af blandinger af antistoffer
|
|
EP1539946A4
(en)
*
|
2002-09-09 |
2006-03-15 |
California Inst Of Techn |
METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
|
|
WO2004067725A2
(en)
*
|
2003-01-30 |
2004-08-12 |
Regeneron Pharmaceuticals, Inc. |
Methods of identifying modulators of nmur2-mediated activity
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
ES2463476T3
(es)
|
2004-10-19 |
2014-05-28 |
Regeneron Pharmaceuticals, Inc. |
Método para generar un ratón homocigótico para una modificación genética
|
|
US20060117396A1
(en)
*
|
2004-11-30 |
2006-06-01 |
Murphy Andrew J |
Assay methods for identifying modulators of OPSDL3 and transgenic knockouts
|
|
ME00832B
(me)
|
2007-03-22 |
2012-03-20 |
Ucb Biopharma Sprl |
Vezivni proteini uključujući antitjela, derivate antitjela i fragmente antitjela, koji specifično vezuju cd154 i njihova upotreba
|
|
PL2602323T3
(pl)
|
2007-06-01 |
2018-06-29 |
Open Monoclonal Technology, Inc. |
Kompozycje i sposoby hamowania endogennych genów immunoglobin i wytwarzania transgenicznych ludzkich przeciwciał typu idiotypowego
|
|
KR20100103810A
(ko)
*
|
2007-12-10 |
2010-09-28 |
알리바 바이오파마수티컬스, 아이엔씨. |
동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
|
|
CA2720903C
(en)
*
|
2008-04-14 |
2019-01-15 |
Sangamo Biosciences, Inc. |
Linear donor constructs for targeted integration
|
|
US20090328240A1
(en)
*
|
2008-06-24 |
2009-12-31 |
Sing George L |
Genetically modified mice as predictors of immune response
|
|
DE102008002715A1
(de)
*
|
2008-06-27 |
2009-12-31 |
Evonik Röhm Gmbh |
2-Hydroxyisobuttersäure produzierende rekombinante Zelle
|
|
AU2009298458B2
(en)
|
2008-09-30 |
2015-10-08 |
Ablexis, Llc |
Non-human mammals for the production of chimeric antibodies
|
|
DK3622815T3
(da)
|
2009-07-08 |
2023-06-26 |
Kymab Ltd |
Gnavermodeller og terapeutiske molekyler
|
|
US9445581B2
(en)
|
2012-03-28 |
2016-09-20 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
EP4502152A3
(en)
|
2009-10-06 |
2025-04-30 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice and engraftment
|
|
CA2779858C
(en)
|
2009-10-29 |
2019-10-29 |
Regeneron Pharmaceuticals, Inc. |
Multifunctional alleles
|
|
ES2724975T3
(es)
|
2009-12-10 |
2019-09-18 |
Regeneron Pharma |
Ratones que producen anticuerpos de cadena pesada
|
|
CA2784953C
(en)
|
2009-12-21 |
2018-05-22 |
Regeneron Pharmaceuticals, Inc. |
Humanized fc.gamma.r mice
|
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
|
US20120021409A1
(en)
|
2010-02-08 |
2012-01-26 |
Regeneron Pharmaceuticals, Inc. |
Common Light Chain Mouse
|
|
SMT202600080T1
(it)
|
2010-02-08 |
2026-03-09 |
Regeneron Pharma |
Topo con catena leggera comune
|
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
ES2984483T3
(es)
|
2010-03-31 |
2024-10-29 |
Ablexis Llc |
Ingeniería genética de ratones para la producción de anticuerpos quiméricos
|
|
US9242014B2
(en)
|
2010-06-15 |
2016-01-26 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
|
|
PT3034608T
(pt)
|
2010-06-22 |
2019-05-28 |
Regeneron Pharma |
Ratinhos expressando uma cadeia leve híbrida de imunoglobulina com uma região variável humana
|
|
US10793829B2
(en)
|
2010-07-26 |
2020-10-06 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
CN103025884B
(zh)
|
2010-07-26 |
2015-11-25 |
特里安尼公司 |
转基因动物和使用方法
|
|
US10662256B2
(en)
|
2010-07-26 |
2020-05-26 |
Trianni, Inc. |
Transgenic mammals and methods of use thereof
|
|
SMT201700023T1
(it)
|
2010-08-02 |
2017-03-08 |
Regeneron Pharma |
Topi che producono proteine leganti vl
|
|
EP2638155A1
(en)
|
2010-11-08 |
2013-09-18 |
Kymab Limited |
Cells & vertebrates for enhanced somatic hypermutation and class switch recombination
|
|
EP3604339B1
(en)
|
2011-01-14 |
2021-03-10 |
The Regents Of The University Of California |
Therapeutic antibodies against ror-1 protein and methods for use of same
|
|
SG10202008003VA
(en)
|
2011-02-15 |
2020-10-29 |
Regeneron Pharma |
Humanized m-csf mice
|
|
US10920242B2
(en)
|
2011-02-25 |
2021-02-16 |
Recombinetics, Inc. |
Non-meiotic allele introgression
|
|
ME02106B
(me)
|
2011-02-25 |
2015-10-20 |
Regeneron Pharma |
Miševi sa adam6
|
|
PL2631654T3
(pl)
|
2011-05-12 |
2015-09-30 |
Regeneron Pharma |
Oznaczenie uwalniania neuropeptydu dla kanałów sodowych
|
|
HUE047278T2
(hu)
|
2011-08-05 |
2020-04-28 |
Regeneron Pharma |
Humanizált univerzális könnyûláncú egerek
|
|
BR112014006394A2
(pt)
|
2011-09-19 |
2017-03-28 |
Kymab Ltd |
manipulação de diversidade genética de imunoglobulina e terapêuticos multi-anticorpos
|
|
EP2758534B1
(en)
|
2011-09-19 |
2020-04-29 |
Kymab Limited |
Animals, repertoires & methods for the production of human antibodies
|
|
WO2013045916A1
(en)
|
2011-09-26 |
2013-04-04 |
Kymab Limited |
Chimaeric surrogate light chains (slc) comprising human vpreb
|
|
SG11201401181YA
(en)
|
2011-10-17 |
2014-04-28 |
Regeneron Pharma |
Restricted immunoglobulin heavy chain mice
|
|
GB2496375A
(en)
|
2011-10-28 |
2013-05-15 |
Kymab Ltd |
A non-human assay vertebrate comprising human antibody loci and human epitope knock-in, and uses thereof
|
|
SMT202200205T1
(it)
|
2011-10-28 |
2022-07-21 |
Regeneron Pharma |
Topi geneticamente modificati che esprimono molecole chimeriche del complesso maggiore di istocompatibilità (mhc) ii
|
|
CN107858333B
(zh)
|
2011-10-28 |
2022-05-27 |
瑞泽恩制药公司 |
T细胞受体基因修饰小鼠
|
|
US9043996B2
(en)
|
2011-10-28 |
2015-06-02 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
US9591835B2
(en)
|
2011-10-28 |
2017-03-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex animals
|
|
SMT201900478T1
(it)
|
2011-10-28 |
2019-09-09 |
Regeneron Pharma |
Topi con complesso maggiore di istocompatibilita' geneticamente modificati
|
|
AU2012332894A1
(en)
|
2011-10-31 |
2014-05-08 |
Merck Sharp & Dohme Corp. |
Nano-suspension process
|
|
US9253965B2
(en)
|
2012-03-28 |
2016-02-09 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
GB201122047D0
(en)
|
2011-12-21 |
2012-02-01 |
Kymab Ltd |
Transgenic animals
|
|
SG10201605675WA
(en)
|
2011-12-20 |
2016-09-29 |
Regeneron Pharma |
Humanized light chain mice
|
|
EP3597038B1
(en)
|
2012-02-01 |
2021-04-21 |
Regeneron Pharmaceuticals, Inc. |
Humanized rodents that express heavy chains containing vl domains
|
|
MX353278B
(es)
|
2012-03-06 |
2018-01-05 |
Regeneron Pharma |
Raton con cadena ligera comun.
|
|
EP3539374A1
(en)
|
2012-03-16 |
2019-09-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals expressing ph-sensitive immunoglobulin sequences
|
|
EP2825036B1
(en)
|
2012-03-16 |
2018-05-02 |
Regeneron Pharmaceuticals, Inc. |
Histidine engineered light chain antibodies and genetically modified rodents for generating the same
|
|
WO2013138681A1
(en)
|
2012-03-16 |
2013-09-19 |
Regeneron Pharmaceuticals, Inc. |
Mice that produce antigen-binding proteins with ph-dependent binding characteristics
|
|
US20140013456A1
(en)
|
2012-03-16 |
2014-01-09 |
Regeneron Pharmaceuticals, Inc. |
Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
|
|
US10251377B2
(en)
|
2012-03-28 |
2019-04-09 |
Kymab Limited |
Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
|
|
SG11201405059XA
(en)
|
2012-03-28 |
2014-09-26 |
Kymab Ltd |
Transgenic non-human vertebrate for the expression of class - switched, fully human, antibodies
|
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
|
SG11201406547YA
(en)
|
2012-04-25 |
2014-11-27 |
Regeneron Pharma |
Nuclease-mediated targeting with large targeting vectors
|
|
ME03551B
(me)
|
2012-06-12 |
2020-07-20 |
Regeneron Pharma |
Humanizovane nehumane živoтinje sa ograničenim lokusima imunoglobulinskog тeškog lanca
|
|
AR091482A1
(es)
*
|
2012-06-21 |
2015-02-04 |
Recombinetics Inc |
Celulas modificadas geneticamente y metodos par su obtencion
|
|
TWI606063B
(zh)
|
2012-08-23 |
2017-11-21 |
艾澤西公司 |
結合至１５８ｐ１ｄ７蛋白之抗體藥物結合物（ａｄｃ）
|
|
ES2702315T3
(es)
|
2012-08-24 |
2019-02-28 |
Univ California |
Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
|
|
UA118090C2
(uk)
*
|
2012-09-07 |
2018-11-26 |
ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі |
Спосіб інтегрування послідовності нуклеїнової кислоти, що представляє інтерес, у ген fad2 у клітині сої та специфічний для локусу fad2 білок, що зв'язується, здатний індукувати спрямований розрив
|
|
FI2892330T3
(fi)
|
2012-09-07 |
2023-03-25 |
Univ Yale |
Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi
|
|
MX377561B
(es)
|
2012-11-05 |
2025-03-10 |
Regeneron Pharma |
Animales no humanos genéticamente modificados y métodos de uso de los mismos.
|
|
MY178882A
(en)
|
2013-02-20 |
2020-10-21 |
Regeneron Pharma |
Non-human animals with modified immunoglobulin heavy chain sequences
|
|
CN111484999B
(zh)
|
2013-02-20 |
2024-10-25 |
瑞泽恩制药公司 |
人源化的t细胞共受体的小鼠
|
|
MX384291B
(es)
|
2013-02-20 |
2025-03-14 |
Regeneron Pharma |
Modificación genética de ratas.
|
|
US20150342163A1
(en)
|
2013-02-22 |
2015-12-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified major histocompatibility complex mice
|
|
EP3699190B9
(en)
|
2013-02-22 |
2023-10-04 |
Regeneron Pharmaceuticals, Inc. |
Murine cell expressing humanized major histocompatibility complex
|
|
CA2902543A1
(en)
|
2013-03-11 |
2014-10-09 |
Regeneron Pharmaceuticals, Inc. |
Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
|
|
JP6456350B2
(ja)
|
2013-03-11 |
2019-01-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス
|
|
EP4545567A3
(en)
|
2013-03-13 |
2025-08-13 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
|
HK1218550A1
(zh)
|
2013-03-13 |
2017-02-24 |
Regeneron Pharmaceuticals, Inc. |
常見輕鏈小鼠
|
|
US9788534B2
(en)
|
2013-03-18 |
2017-10-17 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
DK3456831T3
(da)
|
2013-04-16 |
2021-09-06 |
Regeneron Pharma |
Målrettet modifikation af rottegenom
|
|
US9783618B2
(en)
|
2013-05-01 |
2017-10-10 |
Kymab Limited |
Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
|
|
US11707056B2
(en)
|
2013-05-02 |
2023-07-25 |
Kymab Limited |
Animals, repertoires and methods
|
|
US9783593B2
(en)
|
2013-05-02 |
2017-10-10 |
Kymab Limited |
Antibodies, variable domains and chains tailored for human use
|
|
WO2015017552A1
(en)
|
2013-08-01 |
2015-02-05 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to cd37 proteins
|
|
MY198884A
(en)
|
2013-08-07 |
2023-10-02 |
Regeneron Pharma |
Lincrna-deficient non-human animals
|
|
RU2019121863A
(ru)
|
2013-09-18 |
2019-08-29 |
Регенерон Фармасьютикалз, Инк. |
Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения
|
|
TR201901782T4
(tr)
|
2013-09-23 |
2019-03-21 |
Regeneron Pharma |
İnsanlaştirilmiş bi̇r si̇nyal düzenleyi̇ci̇ protei̇n geni̇ne sahi̇p olan i̇nsan dişi hayvanlar.
|
|
AU2014330922A1
(en)
|
2013-10-01 |
2016-03-03 |
Kymab Limited |
Animal models and therapeutic molecules
|
|
RU2671101C1
(ru)
|
2013-11-19 |
2018-10-29 |
Регенерон Фармасьютикалс, Инк. |
Отличные от человека животные, содержащие гуманизированный ген индуцирующего пролиферацию лиганда
|
|
CA2929846C
(en)
|
2013-11-19 |
2020-09-15 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized b-cell activating factor gene
|
|
EP3080279B1
(en)
|
2013-12-11 |
2018-09-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for the targeted modification of a genome
|
|
KR102170502B1
(ko)
*
|
2013-12-11 |
2020-10-28 |
리제너론 파마슈티칼스 인코포레이티드 |
게놈의 표적화된 변형을 위한 방법 및 조성물
|
|
WO2015108102A1
(ja)
|
2014-01-15 |
2015-07-23 |
国立大学法人 群馬大学 |
Ａｔｐ可視化動物およびその用途
|
|
TWI681969B
(zh)
*
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
AU2015231025A1
(en)
|
2014-03-21 |
2016-09-15 |
Regeneron Pharmaceuticals, Inc. |
Vl antigen binding proteins exhibiting distinct binding characteristics
|
|
CA3124228C
(en)
|
2014-03-21 |
2024-05-14 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that make single domain binding proteins
|
|
MX2016014995A
(es)
|
2014-05-19 |
2017-03-31 |
Regeneron Pharma |
Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
|
|
MX373055B
(es)
|
2014-05-30 |
2020-05-20 |
Regeneron Pharma |
Animales con dipeptidil peptidasa iv (dpp4) humanizada.
|
|
HRP20200529T1
(hr)
|
2014-06-06 |
2020-09-04 |
Regeneron Pharmaceuticals, Inc. |
Postupci i pripravci za modificiranje ciljnog lokusa
|
|
IL287519B2
(en)
|
2014-06-19 |
2024-01-01 |
Regeneron Pharma |
Non-human animals having a humanized programmed cell death 1 gene
|
|
ES2781323T3
(es)
|
2014-06-23 |
2020-09-01 |
Regeneron Pharma |
Montaje de ADN mediado por nucleasas
|
|
SI3161128T1
(sl)
|
2014-06-26 |
2019-02-28 |
Regeneron Pharmaceuticals, Inc. |
Postopki in sestavki za ciljano genetsko spremembo in postopki uporabe
|
|
JP2017529841A
(ja)
|
2014-09-19 |
2017-10-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
キメラ抗原受容体
|
|
BR112017007770A2
(pt)
|
2014-10-15 |
2018-01-16 |
Regeneron Pharma |
cultura in vitro, população de hipscs, método para modificar um locus-alvo genômico, e, hipsc.
|
|
KR102531016B1
(ko)
*
|
2014-11-21 |
2023-05-10 |
리제너론 파마슈티칼스 인코포레이티드 |
쌍 형성된 가이드 rna를 사용하는 표적화된 유전자 변형을 위한 방법 및 조성물
|
|
RU2726446C2
(ru)
|
2014-11-24 |
2020-07-14 |
Регенерон Фармасьютикалз, Инк. |
Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
|
|
HUE064960T2
(hu)
|
2014-12-05 |
2024-04-28 |
Regeneron Pharma |
Differenciációs 47 gén humanizált klasztert tartalmazó nem-humán állatok
|
|
CN113412818B
(zh)
|
2014-12-09 |
2022-11-04 |
瑞泽恩制药公司 |
具有人源化分化簇274基因的非人动物
|
|
ES2947714T3
(es)
*
|
2014-12-19 |
2023-08-17 |
Regeneron Pharma |
Métodos y composiciones para la modificación genética dirigida a través de múltiples direccionamientos en un solo paso
|
|
EP3268038B1
(en)
|
2015-03-09 |
2021-05-05 |
Agensys, Inc. |
Antibody drug conjugates (adc) that bind to flt3 proteins
|
|
AU2016233250C1
(en)
|
2015-03-16 |
2022-08-18 |
Regeneron Pharmaceuticals, Inc. |
Non-human animal exhibiting diminished upper and lower motor neuron function and sensory perception
|
|
CA2979702A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
|
EP4248744A3
(en)
|
2015-04-06 |
2023-12-27 |
Regeneron Pharmaceuticals, Inc. |
Humanized t cell mediated immune responses in non-human animals
|
|
ES2950399T3
(es)
|
2015-04-13 |
2023-10-09 |
Regeneron Pharma |
Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos
|
|
WO2016187354A1
(en)
|
2015-05-18 |
2016-11-24 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
EP4679095A3
(en)
|
2015-05-18 |
2026-05-06 |
Agensys, Inc. |
Antibodies that bind to axl proteins
|
|
US10395759B2
(en)
|
2015-05-18 |
2019-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for copy number variant detection
|
|
AU2016270587B2
(en)
|
2015-05-29 |
2020-12-24 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a disruption in a C9ORF72 locus
|
|
CA2995248A1
(en)
|
2015-09-02 |
2017-03-09 |
Regeneron Pharmaceuticals, Inc. |
Rodent model of prostate cancer
|
|
TW202417497A
(zh)
|
2015-10-12 |
2024-05-01 |
美商再生元醫藥公司 |
活化瘦素受體的抗原結合蛋白
|
|
WO2017087780A1
(en)
|
2015-11-20 |
2017-05-26 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized lymphocyte-activation gene 3
|
|
EP3380605A1
(en)
*
|
2015-11-24 |
2018-10-03 |
GlaxoSmithKline Intellectual Property Development Limited |
Transient transfection method for retroviral production
|
|
JP7098521B2
(ja)
*
|
2015-11-24 |
2022-07-11 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
レトロウイルス産生のための安定な細胞株
|
|
US10813346B2
(en)
|
2015-12-03 |
2020-10-27 |
Trianni, Inc. |
Enhanced immunoglobulin diversity
|
|
KR20230006929A
(ko)
|
2016-01-13 |
2023-01-11 |
리제너론 파마슈티칼스 인코포레이티드 |
조작된 중쇄 다양성 영역을 갖는 설치류
|
|
US20170218398A1
(en)
*
|
2016-01-30 |
2017-08-03 |
Markus Alexander Brown |
Method to selectively target cancerous cells for genetic manipulation
|
|
SG11201806176PA
(en)
|
2016-02-04 |
2018-08-30 |
Regeneron Pharma |
Non-human animals having an engineered angptl8 gene
|
|
EP4414484A3
(en)
|
2016-02-04 |
2025-01-15 |
Trianni, Inc. |
Enhanced production of immunoglobulins
|
|
US12071669B2
(en)
|
2016-02-12 |
2024-08-27 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for detection of abnormal karyotypes
|
|
CN109195443A
(zh)
|
2016-02-16 |
2019-01-11 |
雷杰纳荣制药公司 |
具有突变型犬尿氨酸酶基因的非人动物
|
|
DK3422845T3
(da)
|
2016-02-29 |
2021-08-30 |
Regeneron Pharma |
Gnavere med et humaniseret tmprss-gen
|
|
WO2017172958A1
(en)
|
2016-03-29 |
2017-10-05 |
Regeneron Pharmaceuticals, Inc. |
Genetic variant-phenotype analysis system and methods of use
|
|
CN113831407B
(zh)
|
2016-05-20 |
2024-06-11 |
瑞泽恩制药公司 |
用于使用多个引导rna来破坏免疫耐受性的方法
|
|
KR102483193B1
(ko)
|
2016-06-03 |
2023-01-04 |
리제너론 파마슈티칼스 인코포레이티드 |
외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
|
|
TWI767915B
(zh)
|
2016-06-27 |
2022-06-21 |
加州大學董事會 |
Ror-1與btk拮抗劑的組合
|
|
WO2018001241A1
(zh)
|
2016-06-28 |
2018-01-04 |
北京百奥赛图基因生物技术有限公司 |
一种pd-1基因修饰人源化动物模型的构建方法及其应用
|
|
JP2019523009A
(ja)
|
2016-07-29 |
2019-08-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｃ末端切断型フィブリリン−１の発現をもたらす変異を有するマウス
|
|
CN109862785B
(zh)
|
2016-09-30 |
2022-09-06 |
瑞泽恩制药公司 |
C9orf72基因座中具有六核苷酸重复扩增的非人类动物
|
|
SG10201913483XA
(en)
|
2016-11-04 |
2020-03-30 |
Regeneron Pharma |
Non-human animals having an engineered immunoglobulin lambda light chain locus
|
|
IL268049B2
(en)
|
2017-01-19 |
2025-08-01 |
Omniab Inc |
Transgenic rodent human antibodies with multiple immunoglobulin heavy chain loci
|
|
AU2018224227A1
(en)
|
2017-02-27 |
2019-08-29 |
Regeneron Pharmaceuticals, Inc. |
Non-human animal models of Retinoschisis
|
|
KR20200033259A
(ko)
|
2017-07-31 |
2020-03-27 |
리제너론 파마슈티칼스 인코포레이티드 |
생체내에서 CRISPR/Cas-매개된 파괴 또는 삭제 및 외인성 도너 핵산과의 CRISPR/Cas-유도된 재조합을 평가하기 위한 방법 및 조성물
|
|
CN110891420B
(zh)
|
2017-07-31 |
2022-06-03 |
瑞泽恩制药公司 |
Cas转基因小鼠胚胎干细胞和小鼠及其应用
|
|
US20190098879A1
(en)
|
2017-09-29 |
2019-04-04 |
Regeneron Pharmaceuticals, Inc. |
Non-Human Animals Comprising A Humanized TTR Locus And Methods Of Use
|
|
RU2020112751A
(ru)
|
2017-09-29 |
2021-10-29 |
Регенерон Фармасьютикалз, Инк. |
Отличные от человека животные, у которых экспрессируется гуманизированный комплекс c1q
|
|
WO2019072241A1
(en)
*
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
|
|
CN109666701B
(zh)
*
|
2017-10-13 |
2021-08-24 |
百奥赛图(北京)医药科技股份有限公司 |
一种pd-1基因修饰人源化动物模型的构建方法及其应用
|
|
JP7361031B2
(ja)
|
2017-11-30 |
2023-10-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
|
|
HUE060608T2
(hu)
|
2017-12-05 |
2023-03-28 |
Regeneron Pharma |
Genetikailag módosított immunglobulin lambda könnyûlánccal rendelkezõ egerek és azok alkalmazása
|
|
EP3592140A1
(en)
|
2018-03-19 |
2020-01-15 |
Regeneron Pharmaceuticals, Inc. |
Transcription modulation in animals using crispr/cas systems
|
|
IL314733A
(en)
|
2018-03-26 |
2024-10-01 |
Regeneron Pharma |
Humanized rodents for testing therapeutic agents
|
|
PT3773713T
(pt)
|
2018-04-06 |
2025-07-29 |
Regeneron Pharma |
Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia
|
|
US20190370254A1
(en)
|
2018-06-01 |
2019-12-05 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for sparse vector-based matrix transformations
|
|
IL318469A
(en)
|
2018-06-14 |
2025-03-01 |
Regeneron Pharma |
Non-human animals capable of reorganizing transgenic DH-DH, and their uses
|
|
HRP20240999T1
(hr)
|
2018-07-16 |
2024-10-25 |
Regeneron Pharmaceuticals, Inc. |
Glodavački modeli bolesti ditra i njihova upotreba
|
|
CN109504708A
(zh)
*
|
2018-12-03 |
2019-03-22 |
江苏集萃药康生物科技有限公司 |
一种筛选标记自我删除的基因打靶载体及方法
|
|
KR102925054B1
(ko)
|
2018-12-20 |
2026-02-10 |
리제너론 파마슈티칼스 인코포레이티드 |
뉴클레아제-매개 반복부 팽창
|
|
WO2020152607A1
(en)
|
2019-01-22 |
2020-07-30 |
St. Jude Children's Research Hospital |
Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
|
|
CA3125380A1
(en)
*
|
2019-02-18 |
2020-08-27 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. |
Genetically modified non-human animals with humanized immunoglobulin locus
|
|
BR112021016173A2
(pt)
|
2019-02-22 |
2021-11-03 |
Regeneron Pharma |
Roedor geneticamente modificado, métodos de produção de um roedor geneticamente modificado e de produção de um anticorpo anti-nav1.7, célula ou tecido isolado de roedor, linhagem celular imortalizada, embrião de roedor, construto de ácido nucleico de direcionamento, e, hibridoma
|
|
RU2771374C1
(ru)
|
2019-04-04 |
2022-05-04 |
Редженерон Фармасьютикалс, Инк. |
Способы для бесшовного внесения целевых модификаций в направленные векторы
|
|
KR102661779B1
(ko)
*
|
2019-04-04 |
2024-04-30 |
리제너론 파마슈티칼스 인코포레이티드 |
인간화 응고 인자 12 좌위를 포함하는 비-인간 동물
|
|
EP3955957A1
(en)
|
2019-04-15 |
2022-02-23 |
Qwixel Therapeutics LLC |
Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
|
|
US11891618B2
(en)
|
2019-06-04 |
2024-02-06 |
Regeneron Pharmaceuticals, Inc. |
Mouse comprising a humanized TTR locus with a beta-slip mutation and methods of use
|
|
MX2021014893A
(es)
|
2019-06-05 |
2022-03-11 |
Regeneron Pharma |
Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos.
|
|
MX2021015122A
(es)
|
2019-06-07 |
2022-04-06 |
Regeneron Pharma |
Animales no humanos que comprenden un locus de albumina humanizado.
|
|
EP3990475A1
(en)
|
2019-06-27 |
2022-05-04 |
Regeneron Pharmaceuticals, Inc. |
Modeling tdp-43 proteinopathy
|
|
RS66218B1
(sr)
|
2019-07-01 |
2024-12-31 |
Tonix Pharma Ltd |
Anti-cd154 antitela i njihove upotrebe
|
|
EP4017542A1
(en)
|
2019-10-04 |
2022-06-29 |
Tae Life Sciences |
Antibody compositions comprising fc mutations and site-specific conjugation properties
|
|
WO2021108363A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-mediated upregulation of humanized ttr allele
|
|
WO2021154791A1
(en)
|
2020-01-28 |
2021-08-05 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized pnpla3 locus and methods of use
|
|
EP4099821A1
(en)
|
2020-02-07 |
2022-12-14 |
Regeneron Pharmaceuticals, Inc. |
<smallcaps/>? ? ?klkb1? ? ? ? ?non-human animals comprising a humanizedlocus and methods of use
|
|
US20230102342A1
(en)
|
2020-03-23 |
2023-03-30 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use
|
|
JP7765403B2
(ja)
|
2020-04-21 |
2025-11-06 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ｃｘｃｌ１３遺伝子を有する非ヒト動物
|
|
JP2023529846A
(ja)
|
2020-06-02 |
2023-07-12 |
バイオサイトジェン ファーマシューティカルズ （ベイジン） カンパニー リミテッド |
共通軽鎖免疫グロブリン遺伝子座を有する遺伝子改変非ヒト動物
|
|
RU2751237C1
(ru)
*
|
2020-06-10 |
2021-07-12 |
Регенерон Фармасьютикалс, Инк. |
Способы и композиции для направленной модификации генома
|
|
WO2021261620A1
(ko)
|
2020-06-25 |
2021-12-30 |
주식회사 휴맵 |
이형접합성 형질전환 동물
|
|
US20220090060A1
(en)
|
2020-09-11 |
2022-03-24 |
Regeneron Pharmaceuticals, Inc. |
Identification and production of antigen-specific antibodies
|
|
KR20230078677A
(ko)
|
2020-10-01 |
2023-06-02 |
리제너론 파마슈티칼스 인코포레이티드 |
인간 cr1을 발현하는 설치류 동물
|
|
US12012441B2
(en)
|
2020-10-26 |
2024-06-18 |
Neptune Biosciences Llc |
Engineered human IL-21 cytokines and methods for using the same
|
|
CN116848254B
(zh)
|
2020-12-16 |
2026-03-17 |
瑞泽恩制药公司 |
表达人源化Fcα受体的小鼠
|
|
JP2024500153A
(ja)
|
2020-12-21 |
2024-01-04 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
ヒト化ｔｓｌｐ遺伝子、ヒト化ｔｓｌｐ受容体遺伝子、及び／又はヒト化ｉｌ７ｒａ遺伝子を有する非ヒト動物
|
|
CA3165366A1
(en)
|
2020-12-23 |
2022-06-30 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses thereof
|
|
WO2022150452A1
(en)
|
2021-01-06 |
2022-07-14 |
Seth Lederman |
Methods of inducing immune tolerance with modified anti-cd154 antibodies
|
|
CN118511853A
(zh)
|
2021-03-31 |
2024-08-20 |
瑞泽恩制药公司 |
包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
|
|
US20240199725A1
(en)
|
2021-04-16 |
2024-06-20 |
Korea University Research And Business Foundation |
Human antibody targeting covid-19 virus
|
|
CA3221878A1
(en)
|
2021-06-18 |
2022-12-22 |
David Stover |
Fusion protein composition(s) comprising masked type i interferons (ifna and ifnb) for use in the treatment of cancer and methods thereof
|
|
US20240415980A1
(en)
|
2021-10-28 |
2024-12-19 |
Regeneron Pharmaceuticals, Inc. |
Crispr/cas-related methods and compositions for knocking out c5
|
|
KR20240117571A
(ko)
|
2021-12-08 |
2024-08-01 |
리제너론 파마슈티칼스 인코포레이티드 |
돌연변이 마이오실린 질환 모델 및 이의 용도
|
|
US20250049006A1
(en)
|
2021-12-20 |
2025-02-13 |
C/O Regeneron Pharmaceuticals, Inc. |
Non-human animals comprising humanized ace2 and tmprss loci
|
|
WO2023150798A1
(en)
|
2022-02-07 |
2023-08-10 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for defining optimal treatment timeframes in lysosomal disease
|
|
AU2023218391A1
(en)
|
2022-02-11 |
2024-07-11 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for screening 4r tau targeting agents
|
|
EP4514125A1
(en)
|
2022-04-26 |
2025-03-05 |
Regeneron Pharmaceuticals, Inc. |
A rodent model of fibrodysplasia ossificans progressiva
|
|
US20250344681A1
(en)
|
2022-05-31 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Animal model of tdp-43 proteinopathy
|
|
WO2023235725A2
(en)
|
2022-05-31 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Crispr-based therapeutics for c9orf72 repeat expansion disease
|
|
US20230417899A1
(en)
|
2022-06-27 |
2023-12-28 |
Oshkosh Corporation |
Position tracking for a lift device
|
|
IL318159A
(en)
|
2022-07-19 |
2025-03-01 |
Regeneron Pharma |
Genetically modified animal model and its use to model the human immune system
|
|
AU2023347224A1
(en)
|
2022-09-22 |
2025-03-20 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mice expressing components of human cellular immune system
|
|
EP4593590A1
(en)
|
2022-09-29 |
2025-08-06 |
Regeneron Pharmaceuticals, Inc. |
Correction of hepatosteatosis in humanized liver animals through restoration of il6/il6r/gp130 signaling in human hepatocytes
|
|
AU2024214456A1
(en)
|
2023-02-01 |
2025-07-03 |
Regeneron Pharmaceuticals, Inc. |
Animals comprising a modified klhdc7b locus
|
|
AU2024304180A1
(en)
|
2023-06-13 |
2026-01-08 |
Adcentrx Therapeutics, Inc. |
Methods and compositions related to antibodies and antibody drug conjugates (adcs) that bind nectin-4 proteins
|
|
KR20260025082A
(ko)
|
2023-06-16 |
2026-02-23 |
리제너론 파마슈티칼스 인코포레이티드 |
벡터, 유전자 변형 세포, 및 그것을 포함하는 유전자 변형 비인간 동물
|
|
WO2025122669A1
(en)
|
2023-12-05 |
2025-06-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having a humanized complement factor b gene
|
|
US20250255282A1
(en)
|
2024-02-08 |
2025-08-14 |
Regeneron Pharmaceuticals, Inc. |
Vectors, genetically modified cells, and genetically modified non-human animals comprising the same
|
|
WO2025212991A1
(en)
|
2024-04-05 |
2025-10-09 |
Regeneron Pharmaceuticals, Inc. |
Rodent models of disease
|
|
WO2025235388A1
(en)
|
2024-05-06 |
2025-11-13 |
Regeneron Pharmaceuticals, Inc. |
Transgene genomic identification by nuclease-mediated long read sequencing
|
|
WO2025250495A1
(en)
|
2024-05-28 |
2025-12-04 |
Regeneron Pharmaceuticals, Inc. |
Acceleration of human hepatocyte engraftment in humanized liver animals by supplementing paracrine ligands or agonists that activate human liver regeneration signals
|
|
WO2025264533A1
(en)
|
2024-06-17 |
2025-12-26 |
Adcentrx Therapeutics Inc. |
Methods and compositions related to antibody drug conjugates (adcs) that bind steap-1 proteins
|
|
WO2026030428A2
(en)
|
2024-08-01 |
2026-02-05 |
Regeneron Pharmaceuticals, Inc. |
Prostate-specific antigen peptides and uses thereof
|
|
WO2026035843A2
(en)
|
2024-08-06 |
2026-02-12 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof
|
|
WO2026039661A1
(en)
|
2024-08-15 |
2026-02-19 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals with humanized fc epsilon receptors that lack functional alpha-1, 3-galactosyltransferase (ggta1)
|